Allergic Rhinitis
📧 Sign up to get email alerts when something new happens for Allergic Rhinitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-03-17FDA Approved: RUGBY MOMETASONE FUROATE NASAL — Original Application (Rugby Laboratories)
FDA approved Rugby Mometasone Furoate Nasal from Rugby Laboratories under an original NDA. The nasal corticosteroid is indicated for allergi…
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422) [Phase 4]
Phase 4 trial comparing systemic exposure from different ciclesonide formulations (nasal spray, nasal aerosol, and orally inhaled) in allerg…
-
CLINICAL_TRIALS trial_result · 2022-02-22Clinical Trial Update: DYmista NAsal Spray in CHInese Patients [Phase 3]
Phase 3 clinical trial update for DYmista Nasal Spray in Chinese patients with allergic rhinitis has completed.
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03829)(COMPLETED) [Phase 3]
A Phase 3 completed trial comparing taste test between desloratadine and cetirizine syrup in children with allergic rhinitis.
-
CLINICAL_TRIALS trial_result · 2022-02-16Clinical Trial Update: Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826) [Phase 3]
A Phase 3 clinical trial comparing desloratadine and cetirizine syrup in children with allergic rhinitis has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: "Efficacy and Safety of Phlai Capsule Compared to Placebo as the Treatment in Allergic Rhinitis Patients" [Phase 3]
Phase 3 trial comparing Phlai Capsule to placebo in allergic rhinitis has completed.
-
CLINICAL_TRIALS trial_result · 2022-01-19Clinical Trial Update: Treatment of Allergic Rhinitis and Chronic Polypous Rhinosinusitis With Olfactory Mucosa-derived Mesenchymal Stem Cells [Phase 1, Phase 2]
Clinical trial investigating olfactory mucosa-derived mesenchymal stem cells for allergic rhinitis and chronic rhinosinusitis with polyps; c…
-
FDA approval · 2022-01-13FDA Approved: RYALTRIS — Original Application (HIKMA SPECIALTY USA INC.)
FDA approved the original application for RYALTRIS, a fixed-dose nasal spray combining olopatadine HCl and mometasone furoate by Hikma Speci…
-
FDA approval · 2021-12-14FDA Approved: ZYRTEC — Supplemental Application (Kenvue Brands LLC)
FDA approves a supplemental application for ZYRTEC (cetirizine hydrochloride) submitted by Kenvue Brands LLC.
-
FDA approval · 2021-11-23FDA Approved: ADVIL ALLERGY SINUS — Supplemental Application (Haleon US Holdings LLC)
FDA approved a supplemental application for Advil Allergy Sinus, a combination product containing chlorpheniramine maleate, ibuprofen, and p…
-
FDA approval · 2021-11-03FDA Approved: ZYRTEC-D — Supplemental Application (Kenvue Brands LLC)
FDA approved a supplemental application for ZYRTEC-D (cetirizine hydrochloride and pseudoephedrine hydrochloride) from Kenvue Brands LLC, au…
-
CLINICAL_TRIALS research · 2021-11-03Clinical Trial Update: Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen [NA]
Clinical trial update describing development of human nasal challenge models with microbial constituents and grass pollen; study completed w…
-
FDA approval · 2021-11-01FDA Approved: ASTEPRO ALLERGY — Supplemental Application (Bayer HealthCare LLC.)
FDA approved a supplemental application for AStepro Allergy (azelastine HCl) from Bayer HealthCare LLC, resulting in updated labeling for th…
-
FDA approval · 2021-10-15FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA has approved a supplemental application for montelukast sodium submitted by Torrent Pharmaceuticals Limited.
-
FDA approval · 2021-10-15FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Torrent Pharmaceuticals Limited's Montelukast Sodium under ANDA 201515, clearing regulatory appr…
-
CLINICAL_TRIALS trial_result · 2021-10-14Clinical Trial Update: Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline [Phase 2]
Phase 2 trial update evaluating topical minocycline for suppression of cutaneous allergic responses and pruritus.
-
CLINICAL_TRIALS trial_result · 2021-09-10Clinical Trial Update: Early Intervention in Allergic Patients [Phase 4]
Phase 4 clinical trial update on early intervention in allergic rhinitis due to weed pollen involving montelukast.
-
FDA approval · 2021-07-30FDA Approved: MONTELUKAST SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Aurobindo Pharma Limited to market Montelukast sodium as a generic product.
-
CLINICAL_TRIALS trial_result · 2021-07-13Clinical Trial Update: Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma) [Phase 4]
Phase 4 clinical trial update on the immunologic basis of anti-IgE therapy in patients with asthma and related allergic conditions.
-
FDA approval · 2021-07-12FDA Approved: PROMETHAZINE HYDROCHLORIDE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved promethazine hydrochloride under an original ANDA for Quagen Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2021-07-12Clinical Trial Update: Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age [Phase 4]
Phase 4 clinical trial comparing montelukast to intranasal fluticasone for managing allergic rhinitis in children aged 2 to 5.
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Novel Dose Adjustment Schedule for Late Injection in SCIT in AR [Phase 4]
Phase 4 trial update evaluating a novel dose adjustment schedule for late injection in subcutaneous immunotherapy for allergic rhinitis.
-
FDA approval · 2021-06-17FDA Approved: ASTEPRO ALLERGY — Original Application (Bayer HealthCare LLC.)
FDA approved ASTEPRO ALLERGY (azelastine hydrochloride) under Bayer HealthCare LLC.'s original NDA, establishing its intranasal antihistamin…
-
CLINICAL_TRIALS trial_result · 2021-06-04Clinical Trial Update: Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers. [Phase 1]
Phase 1 trial evaluating nasal allergen challenge effects on nasal inflammation comparing E-cigarette users, cigarette smokers, and non-smok…
-
FDA approval · 2021-05-07FDA Approved: LORATADINE — Original Application (Camber Consumer Care Inc)
The FDA approved Camber Consumer Care Inc's loratadine product under an Original Application, marking the approval of this generic antihista…